Delivery Order SPE2DB22D3009-SPE2DB25FBD69
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,252.08 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. The contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, served as the prime contractor, with performance of work also...
- The Defense Logistics Agency awarded a delivery order valued at $4,323.00 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM on August 20, 2025, with completion expected by August 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The pharmaceutical product will be performed at the vendor's corporate office location in...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units, valued at $1,315.27. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 8, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its principal...
- The Defense Logistics Agency awarded a delivery order valued at $1,072.56 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This competitive, non-set-aside contract award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract operates under a firm fixed-price delivery order structure,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,538.10 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This non-set-aside, competitively awarded delivery order was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award utilizes firm fixed price pricing and represents a...
- The Defense Logistics Agency awarded a delivery order valued at $1,450.14 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic medication. This non-set-aside, competitively awarded contract reflects a firm fixed price arrangement with an ultimate completion date of August 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, to provide Clindamycin Phosphate 1% Foam in 100 gram units. The $3,572.64 contract has a completion date of February 26, 2024 and was awarded on February 23, 2024. Amerisourcebergen Drug Corp, as the prime contractor, will deliver the pharmaceutical product from its corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $3,700.26 under a firm fixed price contract. This non-set-aside delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $2,491.58 for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic medication. The contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, and represents a firm fixed-price procurement with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,425.95 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam in 50-gram units. This contract, awarded on August 11, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was competitively procured through...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD69Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,347.82 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam in 100GM units. This award, issued on August 21, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal procurement requirements through open competition. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a leading pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. The company's robust contract portfolio with the DLA demonstrates its established role as a prime vendor for diverse therapeutic categories, including specialty medications, brand-name and generic drugs, and medical supplies essential to defense health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 8/21/25 |